The company will use the investment to further its radar-based monitoring application technology. Xandar’s system received FDA clearance, according to a Feb. 27 Portfolia news release shared with Becker’s.
Portfolia participated in the company’s $10 million series A financing round. The financial terms of this investment were not disclosed.
“Our radar-based solutions represent the future of healthcare and patient monitoring, opening countless doors for healthcare providers and enabling people everywhere to achieve a new standard of quality in the predictive and preventive care they receive,” Sam Yang, founder and CEO of Xandar Kardian, said in the release. “Portfolia’s continued support of Xandar Kardian, highlighted by this significant investment, speaks volumes about how much they align with our mission and believe in the life-saving capabilities of our technology.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.